Latest period
$748.43M
YoY change
-41.5%
5Y CAGR
+13.7%
Peak year (2024)
$1.31B
Latest annual
$768.16M
Total Debt history chart for Insmed (INSM) from 1999 to 2025
Latest: $768.16M
Total Debt growth chart for Insmed (INSM) from 1999 to 2025
Latest: -41.5%
Total Debt history table for Insmed (INSM) from 1999 to 2025
| 2025 | $768.16M | -41.5% | −$545.96M | ||
| 2024 | $1.31B | +9.1% | +$110.13M | ||
| 2023 | $1.20B | +2.2% | +$26.13M | ||
| 2022 | $1.18B | +92.4% | +$565.60M | ||
| 2021 | $612.27M | +51.2% | +$207.43M | ||
| 2020 | $404.84M | +2.0% | +$7.80M | ||
| 2019 | $397.04M | +25.4% | +$80.48M | ||
| 2018 | $316.56M | +469.7% | +$260.99M | ||
| 2017 | $55.57M | +1.4% | +$776.00K | ||
| 2016 | $54.79M | +117.9% | +$29.65M | ||
| 2015 | $25.14M | +1.1% | +$284.00K | ||
| 2014 | $24.86M | +26.3% | +$5.17M | ||
| 2013 | $19.68M | +1.5% | +$297.00K | ||
| 2012 | $19.39M | +6824.3% | +$19.11M | ||
| 2011 | $280.00K | +70.7% | +$116.00K | ||
| 2010 | $164.00K | -21.2% | −$44.00K | ||
| 2009 | $208.00K | -90.1% | −$1.89M | ||
| 2008 | $2.10M | -37.7% | −$1.27M | ||
| 2007 | $3.37M | +6.7% | +$213.00K | ||
| 2006 | $3.16M | -50.9% | −$3.28M | ||
| 2005 | $6.44M | — | +$6.44M | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | $0.00 | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | $0.00 | ||
| 1999 | $0.00 | — | — |
- 2025$768.16M-41.5%
- 2024$1.31B+9.1%
- 2023$1.20B+2.2%
- 2022$1.18B+92.4%
- 2021$612.27M+51.2%
- 2020$404.84M+2.0%
- 2019$397.04M+25.4%
- 2018$316.56M+469.7%
- 2017$55.57M+1.4%
- 2016$54.79M+117.9%
- 2015$25.14M+1.1%
- 2014$24.86M+26.3%
- 2013$19.68M+1.5%
- 2012$19.39M+6824.3%
- 2011$280.00K+70.7%
- 2010$164.00K-21.2%
- 2009$208.00K-90.1%
- 2008$2.10M-37.7%
- 2007$3.37M+6.7%
- 2006$3.16M-50.9%
- 2005$6.44M—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
- 2001$0.00—
- 2000$0.00—
- 1999$0.00—
Total Debt values are taken from Insmed's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Debt at Insmed (INSM)
According to Insmed's latest reported financial statements, the company's latest reported total debt is $748.43M. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — compare with cash on hand for net leverage, and total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Insmed (INSM) reported total debt of $768.16M – plunged 41.5% year-over-year.
Insmed total debt has grown on net over the period, with a +13.7% compound annual growth rate over 2020–2025 (5 years).
2024 marks the peak total debt at $1.31B, with the historical low of $0.00 recorded in 1999.
Insmed Total Debt by Year
Insmed Total Debt 2025: $768.16M
2025's total debt for Insmed came in at $768.16M, plunged 41.5% below 2024.
Insmed Total Debt 2024: $1.31B
Insmed posted total debt of $1.31B in 2024, grew 9.1% from 2023. This figure represents the highest annual value in the available history.
Insmed Total Debt 2023: $1.20B
In 2023, Insmed reported total debt of $1.20B, edged up 2.2% from 2022.
Insmed Total Debt 2022: $1.18B
Insmed total debt in 2022 was $1.18B, surged 92.4% from 2021.
Insmed Total Debt 2021: $612.27M
Insmed total debt in 2021 was $612.27M.
See more financial history for Insmed (INSM).
Sector peers by Total Debt
Healthcare peers of Insmed (INSM), ranked by their latest total debt
| $78.39B | |
| $69.07B | |
| $54.60B | |
| $50.53B | |
| $47.93B | |
| $42.50B | |
| $29.70B | |
| $20.59B |
- $78.39B
- $69.07B
- $54.60B
- $50.53B
- $47.93B
- $42.50B
- $29.70B
- $20.59B
Frequently asked questions
Insmed (INSM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation